CQUniversity
Browse

File(s) not publicly available

New generation drugs for treatment of multiple myeloma

journal contribution
posted on 2023-11-29, 01:08 authored by Fehaid Alanazi, Faith AA Kwa, Genia BurchallGenia Burchall, Denise E Jackson
Multiple myeloma (MM), a plasma cell malignancy, is characterised by lesions in multiple bones involving transformed, matured post-follicular B cells. The course of the disease involves an initial development of monoclonal gammopathy of undetermined significance (MGUS), followed by smouldering MM, before the full MM disease emerges. Despite novel therapies, MM remains incurable, managed by combination therapies, including proteasome inhibitors (PIs), immunomodulators (IMiDs) and anti-human CD38 (daratumumab). MM patients have an increased risk of thromboembolic events due to combination treatments with IMiDs, PIs and anti-human CD38 antibody, and steroids. This review will examine the efficacy and pro-thrombotic effects of MM therapies.

History

Volume

25

Issue

2

Start Page

367

End Page

379

Number of Pages

13

eISSN

1878-5832

ISSN

1359-6446

Publisher

Elsevier

Language

en

Peer Reviewed

  • Yes

Open Access

  • No

Era Eligible

  • Yes

Journal

Drug Discovery Today

Usage metrics

    CQUniversity

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC